IDEAYA Biosciences (NASDAQ:IDYA – Get Free Report) is one of 842 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its competitors? We will compare IDEAYA Biosciences to similar businesses based on the strength of its risk, profitability, analyst recommendations, institutional ownership, valuation, dividends and earnings.
Analyst Recommendations
This is a summary of recent ratings and price targets for IDEAYA Biosciences and its competitors, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| IDEAYA Biosciences | 1 | 1 | 13 | 0 | 2.80 |
| IDEAYA Biosciences Competitors | 9920 | 15327 | 45725 | 1601 | 2.54 |
IDEAYA Biosciences presently has a consensus price target of $49.55, suggesting a potential upside of 87.03%. As a group, “Biotechnology” companies have a potential upside of 108.60%. Given IDEAYA Biosciences’ competitors higher probable upside, analysts clearly believe IDEAYA Biosciences has less favorable growth aspects than its competitors.
Earnings and Valuation
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| IDEAYA Biosciences | $218.71 million | -$113.70 million | -5.90 |
| IDEAYA Biosciences Competitors | $738.69 million | $10.07 million | -18.46 |
IDEAYA Biosciences’ competitors have higher revenue and earnings than IDEAYA Biosciences. IDEAYA Biosciences is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Volatility and Risk
IDEAYA Biosciences has a beta of 0.08, meaning that its stock price is 92% less volatile than the S&P 500. Comparatively, IDEAYA Biosciences’ competitors have a beta of -1.85, meaning that their average stock price is 285% less volatile than the S&P 500.
Institutional and Insider Ownership
98.3% of IDEAYA Biosciences shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 4.7% of IDEAYA Biosciences shares are owned by company insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares IDEAYA Biosciences and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| IDEAYA Biosciences | -1,157.18% | -39.78% | -36.25% |
| IDEAYA Biosciences Competitors | -12,516.26% | -215.91% | -31.70% |
About IDEAYA Biosciences
IDEAYA Biosciences, Inc. is a precision oncology company focused on discovering and developing targeted medicines for patients with cancer. Its research uses insights into tumor genetics and synthetic lethality—the idea that certain genetic changes can make cancer cells especially vulnerable to blocking a related biological pathway—to identify potential treatment targets. The company’s investigational pipeline includes small-molecule therapies aimed at specific cancer-related targets. Programs have included darovasertib, a protein kinase C inhibitor being studied in uveal melanoma, and IDE397, a MAT2A inhibitor being developed for tumors with particular genetic alterations.
Receive News & Ratings for IDEAYA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEAYA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
